Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors

Gynecologic Oncology

Volumn 78, Issue 1, 2000, Pages 16-20

  Engelen, Mirjam J A ^a   De Bruijn, Henk W A ^a   Hollema, Harrie ^a   Ten Hoor, Klaske A ^a   Willemse, Pax H B ^a   Aalders, Jan G ^a   Van Der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; OVARY TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR DIAGNOSIS;

EID: 0033938649     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5811     Document Type: Article

References (15)

1. International Federation of Gynecology and Obstetrics: Classification and strategy of malignant tumors in the female pelvis. Acta Obstet Gynecol Scand 50:1-7, 1971
2. Trimble CL, Trimble EL: Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 55:S52-S61, 1994
3. Tropé C, Kærn J: Prognosis and management of borderline tumours of the ovary. Curr Opin Obstet Gynecol 8:12-16, 1996
4. Kenemans P, Yedema CA, Bon GG, von Mensdorff-Pouilly S: CA 125 in gynecological pathology: A review. Eur J Obstet Gynecol Reprod Biol 49:115-124, 1993
5. De Bruijn HWA, van der Zee AGJ, Aalders JG: The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer. Curr Opin Obstet Gynecol 9:8-13, 1997
6. Kurman RJ: Blaustein's Pathology of the Female Genital Tract. 4th ed. New York, Springer-Verlag, 1994, p 706
7. Motoyama T, Watanabe H, Takeuchi S, Watanabe T, Gotoh S, Okazaki E: Cancer antigen 125, carcinoembryonic antigen and carbohydrate determinant 19-9 in ovarian tumors. Cancer 66:2628-2635, 1990
8. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani G, Bianchi R, Fioretti P: The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis. Gynecol Oncol 44:147-154, 1992
9. Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, Lopez JJ, Ballesta A: A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumor Biol 13:278-286, 1992
10. De Bruijn HWA, Ten Hoor KA, Boonstra H, Marrink J, Krans M, Aalders JG: Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: A comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. Tumor Biol 14:105-115, 1993
11. Tamakoshi K, Kikkawa F, Shibata K, et al.: Clinical value of CA125, CA 19-9, CEA, CA 72-4 and TPA in borderline ovarian tumor. Gynecol Oncol 62:67-72, 1996
12. International Federation of Gynecology and Obstetrics: Changes in definitions of clinical staging for carcinoma of the cervix and the ovary. Am J Obstet Gynecol 156:263-264, 1987
13. Serov SF, Scully RE, Sobin LH: International Histologic Typing of Ovarian Tumors. Geneva, World Health Organization, 1973
14. Lagendijk JH, Mullink H, Van Diest PJ, Meijer CJ: Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: Differential diagnosis between colonie and ovarian carcinomas as primary sites. Hum Pathol 29:491-497, 1998
15. Siriaunkgul S, Robbins KM, McGowan L, Silverberg SG: Ovarian mucinous tumors of low malignant potential: A clinicopathologic study of 54 tumors of intestinal and Mullerian type. Int J Gynecol Pathol 14:198-208, 1995